

Education Needs and Practice Gaps 2024

High Priority Clinical Topics

(Identified in two+ data sources)



Additional Priority Topics

(Identified in one data source)



High Priority Non-Clinical Topics

(Identified in two+ data sources)



Office of Medical Education Committee Members



Members of the Office of Medical Education Needs Assessment Workgroup reviewed a variety of resources to identify the highest priority knowledge and practice gaps among the Academy's members to guide the development of educational activities that will result in improved practice and optimal patient care. The data sources included:

- Evaluation responses from learners who participated in the 2024 AAAAI Annual Meeting
- Questions submitted by healthcare providers to the AAAAI's "Ask the Expert" in 2023
- Current AAAAI educational activities
- ABAI CAP program diplomate scores

The list below includes the knowledge and practice gaps that were most frequently identified through analysis of data sources. *It is not intended to be an exhaustive list*, and those planning education activities are encouraged to use other resources to supplement these suggestions.



High Priority Clinical Topics

Topic	Knowledge and Practice Gaps
Allergens, Allergy Testing and Allergy Therapeutics, including Biologics	<ul style="list-style-type: none">• Practical considerations for the use of biologics in allergic diseases (options, patient choice, costs, logistics, follow-up, adverse reactions)• Component Testing (food, environmental, venom)
Anaphylaxis, Urticaria & Angioedema	<ul style="list-style-type: none">• Diagnosis and treatment of urticaria, particularly chronic spontaneous and chronic inducible urticaria• Diagnosis and treatment of angioedema, especially chronic and hereditary angioedema
Asthma	<ul style="list-style-type: none">• Practical considerations for use of biologics in the treatment of asthma and COPD (options, safety, patient choice, costs)
Drug/Insect/Vaccine Allergy	<ul style="list-style-type: none">• Diagnosis and testing of non-penicillin drug allergy, including skin testing and challenge protocols• De-labeling of penicillin and other drug allergy• Venom allergy testing and treatment• Drug allergy practice parameter update
Food Allergy	<ul style="list-style-type: none">• Food immunotherapy (OIT, EPIT, SLIT) options, protocols and outcomes• Early peanut OIT• Food Challenges• Alpha-gal Syndrome

	<ul style="list-style-type: none">• Omalizumab for food allergy
Immunodeficiency /Immunology	<ul style="list-style-type: none">• Approach to diagnosis of immunodeficiency, including genetic testing• Treatment and long-term management of immunodeficiency• Vaccination in biological therapy and PID diagnosis• Secondary immunodeficiency
Mast Cells and Eosinophilic Disorders	<ul style="list-style-type: none">• Diagnosis and testing of mast cell diseases, including mast cell activation syndrome (MCAS) and HaT• Diagnosis and testing of EGID and hypereosinophilia• Therapeutic advances in mast cell disorders and eosinophilic disorders
Skin Diseases	<ul style="list-style-type: none">• Mimickers of atopic skin diseases• Patch testing• Practice Parameters in atopic dermatitis, including biologics & JAK inhibitors



Additional Clinical Topics

Topic	Knowledge and Practice Gaps
Allergens, Allergy Testing and Allergy Therapeutics, including Biologics	<ul style="list-style-type: none">• Best practices in allergy skin testing and allergy serum testing• Using rush allergen desensitization effectively and safely• Hormonal allergic reactions (progesterone sensitivity)
Anaphylaxis, Urticaria, and HAE	<ul style="list-style-type: none">• Immunomodulatory treatment for chronic urticaria• Perioperative anaphylaxis diagnosis and testing• Implementation of new anaphylaxis practice parameters
Asthma	<ul style="list-style-type: none">• GINA 2023 Global Strategy for Asthma Management and Prevention Guidelines• Advances in asthma and COPD treatment• Guidance on Anti-inflammatory Reliever (AIR)-only treatment vs Maintenance and Reliever Therapy (MART)• Difficult to control asthma, mimickers of asthma
Occupational Allergic Diseases	<ul style="list-style-type: none">• Asthma, contact dermatitis
Immune Mechanisms	<ul style="list-style-type: none">• Overview of the immune response• Microbiome

Drug Allergy	<ul style="list-style-type: none"> • Multiple drug intolerance syndrome
Rhinosinusitis and Ocular Allergy	<ul style="list-style-type: none"> • Allergic Rhinitis • Immunotherapy • Biologics in nasal polyp treatment • Role of aspirin desensitization
Autoimmune & Autoinflammatory Disorders	<ul style="list-style-type: none"> • Diagnosis and treatment of autoimmune and autoinflammatory disorders



High Priority Non-Clinical Topics

Topic	Knowledge and Practice Gaps
Climate Change	<ul style="list-style-type: none"> • Impact of climate change and pollutants on allergic disease
Social Determinants of Health (SDOH)	<ul style="list-style-type: none"> • Screening and addressing SDOH • Improving care in areas with limited resources • Providing equity in care • Increasing underrepresented or rural groups in A/I
Practice Management	<ul style="list-style-type: none"> • Revenue generation, staffing, coding, implementing OIT in clinical practice
Artificial Intelligence	<ul style="list-style-type: none"> • Implementation across multiple areas; clinical practice, education, practice management



Office of Medical Education 2024

***Needs Assessment Workgroup Member / Report Co-Author*

Rebecca Scherzer, MD FAAAAI- Chair	Maureen George, PhD RN AE-C	Caroline Sokol, MD PhD FAAAAI
Edwin Kim, MD FAAAAI - Vice- Chair	Jordana Goldman, MD	Katherine Tuttle, MD
Gerald Lee, MD FAAAAI** - Immediate Past Chair	Alice Hoyt, MD FAAAAI	Dilawar Khokhar, MD** <i>(NAIA appointee to workgroup)</i>
Leonard Bacharier, MD FAAAAI	Shyam Joshi, MD	
Priya Bansal, MD FAAAAI**	Brenna LaBere, MD	
Rohit Divekar, MBBS PhD**	Lily Pien, MD MHPE FAAAAI	
Mary Beth Fasano, MD MSPH FAAAAI	Thanai Pongdee, MD FAAAAI**	

Disclosures

Members of the Office of Medical Education Workgroup disclosed the following relevant relationships, for which all potential conflicts of interest were mitigated:

Dr. Gerald Lee: *Gilead Pharmaceutical (stocks)*

Dr. Priya Bansal: *ALK (speaker), Astra-Zeneca (speaker), Blue-Air (consultant), CSL Behring (speaker), Exhale (speaker), GTI Energy (consultant), Incyte (advisory board), Kalvista (advisory board), Novartis (consultant), Pharming (advisory board), Regeneron/Sanofi (speaker), Roche (consultant), Takeda (speaker)*

Dr. Rohit Divekar: *Novocure (stocks), Quanterix (stocks)*

Dr. Thanai Pongdee: *Blueprint Medicines (advisory board), GlaxoSmithKline (consultant, research grant), Sanofi (research grant)*

Dr. Dilawar Khokar: *Blueprint Medicines (advisory board)*